It effectively inhibits STAT5 signaling in a sub-micromolar concentration and induces tumor regression in chronic myeloid leukemia (CML) xenograft models with good tolerability. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.